736822--7/27/2007--IMMUCOR_INC

related topics
{product, liability, claim}
{cost, operation, labor}
{operation, international, foreign}
{customer, product, revenue}
{competitive, industry, competition}
{product, candidate, development}
{product, market, service}
{financial, litigation, operation}
{personnel, key, retain}
{property, intellectual, protect}
Risks Relating to Our Company A catastrophic event at our Norcross, Georgia facility would prevent us from producing many of our reagent products. Unforeseen product performance problems could prevent us from selling the affected products or even result in a recall of previously-placed products. Any unforeseen delays or costs relating to the planned closure of our Houston facility or difficulties in consolidating our manufacturing facilities could adversely affect our business and operating results. We are highly dependent on our senior management team and other key employees, and the loss of one or more of these employees could adversely affect our operations. Our customers and potential customers may choose to delay significant capital expenditures, which could have an adverse effect on the sales of our instruments. If customers delay integrating our instruments into their blood banking operations, our operating results could be negatively impacted. Our business is concentrated in North America and in order to continue to successfully grow our business, we must expand sales of our products outside North America. Because we sell our products internationally, we could be adversely affected by fluctuations in foreign currency exchange rates. We cannot predict the outcome of pending governmental investigations and other pending legal matters. Our financial performance is highly dependent on the timely and successful introduction of new products and services. We are dependent on some single source suppliers. We may be unable to adequately protect our proprietary technology. Risks Relating to our Industry Government regulation may delay or prevent new product introduction. The industry and market segment in which we operate are highly competitive, and we may not be able to compete effectively with larger companies with greater financial resources than we have. We may be exposed to product liability claims resulting from the use of products we sell and distribute.

Full 10-K form ▸

related documents
736822--8/1/2006--IMMUCOR_INC
736822--7/24/2008--IMMUCOR_INC
780127--1/12/2006--SYNOVIS_LIFE_TECHNOLOGIES__INC
780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC
885725--3/1/2006--BOSTON_SCIENTIFIC_CORP
10456--2/19/2009--BAXTER_INTERNATIONAL_INC
880432--9/28/2009--MISONIX_INC
26172--2/26/2008--CUMMINS_INC
26172--2/28/2006--CUMMINS_INC
26172--2/27/2007--CUMMINS_INC
27096--9/13/2006--DATASCOPE_CORP
1270597--3/23/2007--MERISANT_CO
874716--2/20/2009--IDEXX_LABORATORIES_INC_/DE
1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP
1006195--3/15/2007--MATRIXX_INITIATIVES_INC
911649--4/2/2007--STRATEGIC_DIAGNOSTICS_INC/DE/
27096--9/12/2007--DATASCOPE_CORP
47518--12/6/2006--HILLENBRAND_INDUSTRIES_INC
313143--5/27/2008--HAEMONETICS_CORP
795403--3/1/2010--WATTS_WATER_TECHNOLOGIES_INC
8146--4/16/2008--ASTRO_MED_INC_/NEW/
1110783--10/26/2007--MONSANTO_CO_/NEW/
795403--3/3/2006--WATTS_WATER_TECHNOLOGIES_INC
795403--3/1/2007--WATTS_WATER_TECHNOLOGIES_INC
736822--7/24/2009--IMMUCOR_INC
768408--6/24/2010--CYANOTECH_CORP
880432--9/26/2008--MISONIX_INC
718924--12/27/2006--SPAN_AMERICA_MEDICAL_SYSTEMS_INC
9892--2/26/2008--BARD_C_R_INC_/NJ/
739944--3/15/2007--MEDTOX_SCIENTIFIC_INC